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Purpose or Objective: A new entity of patients with 
recurrent prostate cancer limited to a small number of active 
metastatic lesions is having growing interest: the 
oligometastatic patients. Patients with oligometastatic 
disease could eventually be managed by treating all the 
active lesions with local therapy, i.e. either surgery or 
ablative stereotactic body radiotherapy. This study aims to 
assess the impact of [18F]Choline ([18F]FMCH) PET/CT and 
the use stereotactic body radiotherapy (SBRT) in patients 
(pts) with oligometastatic prostate cancer (PCa). 
 
Material and Methods: Twenty-nine pts with oligometastatic 
PCa (≤3 synchronous active lesions detected with 
[18F]FMCHPET/CT) were treated with repeated salvage SBRT 
until disease progression (development of > three active 
synchronous metastases). Primary endpoint was systemic 
therapy-free survival measured from the baseline 
[18F]FMCHPET/CT. 
 
Results: A total of 45 lesions were treated with SBRT. After a 
median follow-up of 11.5 months (range 3-40 months), 20 pts 
were still in the study and did not receive any systemic 
therapy. Nine pts started systemic therapy, and the median 
time of the primary endpoint was 39.7 months (CI 12.20-
62.14 months). No grade 3 or 4 toxicity was recorded. 
 
Conclusion: Repeated salvage [18F]FMCHPET/CT-guided 
SBRT is well tolerated and could defer the beginning of 
systemic therapy in selected patients with oligometastatic 
PCa. 
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Purpose or Objective: 5-fraction SBRT using CyberKnife is a 
well-established safe alternative treatment for selected low-
risk (LR) and intermediate-risk (IR) prostate cancer.  
The aim of this study is to determine prospectively the 
morbidity (CTCAE) and QOL (auto-administered IPSS) of an 8-
fraction scheme for high-risk (HR), IR and LR using 
tomotherapy. 
 
Material and Methods: Exclusion criteria were T3b-4, GS 9-
10, PSA ≥50, IPSS ≥20.  
Since 2012 eighty-two patients were treated: 41 HR (23/41 
with GS ≥8 or PSA >20 or T3a, and 18/41 with ≥2 
intermediate risk factors), 17 IR (GS 7 or PSA 10-20 or T2b-c), 
and 24 LR.  
57/82 patients received 6-month hormonal therapy (HT).  
8 fractions of 5.65 Gy for HR-IR, and 5.48 Gy for LR patients 
were delivered every other day over about 2.5 weeks. EQD2 
is 92.3 Gy (HR, IR) or 87.4 Gy (LR) for prostate cancer (a/b 
1.5), and 78.2 or 74.3 Gy for late-responding tissues (a/b 3), 
respectively. 
 
Results: Median follow-up was 13.7 months (0.3-40.1). 
No acute/late grade ≥3 events were observed. Late GU or GI 
grade 2 toxicities were far bellow 10% (see Table). We 
observed a slight urinary flare at 18 months. 
 
  
During/following 
SBRT (N=81) 
1 
month 
(N=80) 
6 
months 
(N=66) 
12 
months 
(N=50) 
18 
months 
(N=35) 
24 
months 
(N=27) 
GU 
toxicity 
Grade 
1 41 50.6% 
17 
21.2% 
11 
16.7% 9 18% 3 8.6% 2 7.4% 
 
Grade 
2 17 21% 
3 
3.8% 0 0% 0 0% 2 5.7% 0 0% 
GI 
toxicity 
Grade 
1 26 32.1% 8 10% 6 9.1% 9 18% 7 20% 1 3.7% 
 
Grade 
2 10 12.4% 0 0% 1 1.5% 1 2% 1 2.9% 2 7.4% 
GU / GI 
toxicity 
Grade 
3+ 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 
 
IPSS scores (Q1-7) and patient satisfaction (Q8) returned to 
baseline at 6 months (p=0.21), after they significantly 
worsened at the last fraction (p=0.00), especially the IPSS-
obstructive component (see Figure). 
 
 
 
Without HT, PSA nadir has not been reached yet. Mean value 
at 24 months was 0.66 ng/mL.  
With HT, PSA nadir was reached between 1-6 months and 
then raised up to 0.37 ng/mL average at 18 months (mean 
testosterone 291 ng/dL), to remain steady afterwards. 
No biochemical (nadir+2) /clinical failure was found. One 
unrelated cancer/treatment death occurred during SBRT. 
 
Conclusion: To our knowledge this is the first communication 
of SBRT using helical tomotherapy for localized prostate 
cancer.  
The 8-fraction scheme is being well tolerated, with no 
moderate-severe toxicity, suggesting that this approach is 
safe.  
Longer follow-up is needed to find out whether the delivery 
of equivalent doses near the plateau of the dose-response 
curve (>90 Gy) results in better tumour control in this cohort 
of patients (mostly HR and IR tumours). 
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Purpose or Objective: The use of postoperative radiotherapy 
(RT) in patients (pts) at risk for local recurrence is well 
established for many tumours. The postoperative subgroup of 
the AIRO Working Group on Prostate RT carried out a multi-
institutional prospective study to evaluate the impact of 
Adjuvant RT (PORT) and Salvage RT (SART) on biochemical 
outcomes in prostate cancer pts. 
 
Material and Methods: Between January 2002 and December 
2003, data of 440 pts (mean age: 65 years, range 42-81) 
treated with radical prostatectomy (RP) were collected by 14 
Italian RT Departments. Of the 411 pts available for the 10 
year analysis (median follow up: 111 months), 284 (69.1%) 
received PORT (started <6 months after RP) and 127 
underwent SART because of increasing PSA level after having 
been undetectable or persistently elevated PSA (> 6 months 
after RP). Gleason Score (GS) > 7 and positive surgical 
margins (SM+) have been shown by 69% pts and 74.5% 
respectively; 76.5% presented locally advanced disease (pT3-
4), 27 (6.7%) positive pelvic nodes; 163 pts (40.2%) revealed 
seminal vesicles invasion (SVI). All pts received RT to the 
prostatic fossa (mean dose of 67.8 Gy, range: 60-76). Pelvic 
RT was delivered to 111 pts (27%). Androgen deprivation (AD) 
was prescribed to 47,3% pts. Among 127 SART pts, pre-RT PSA 
level was 1 ng/mL or less in 56 pts (44,1%). 
 
Results: Ten year analysis shows that 259 pts are disease free 
and 331 are still alive. 10 year (10-y) overall survival and 
biochemical control (BC) rate are 75.9% and 57.8% 
respectively. On univariate analysis, PORT versus SART, SVI 
and GS > 7 significantly influenced 10-y BC rate: 62.7% in 
PORT group versus 45.6% SART one (p = 0.003), 56.9% in pts 
with SVI versus 65.6% pts without SVI (p < 0.001), 52.5% if GS 
> 7 and 69.8% if GS < 7 (p= 0.003). SM+, pathological T and N 
stages, AD or pelvic RT had no impact on biochemical 
recurrence rate. SVI and PORT versus SART were variables 
associated with BC on multivariate analysis. Only pre-RT PSA 
level significantly influenced disease free survival in SART 
setting: when the pre-RT PSA was 1 ng/mL or less, 59.8% pts 
were disease free at 10-y compared with 33.5% of those 
treated at PSA levels greater than 1 ng/mL (p= 0.017). 
 
Conclusion: Pts in PORT group, pts without SVI and with GS < 
7 show better BC rates . Postoperative RT delivered in high 
risk prostate cancer patients can reduce the impact of other 
common unfavourable prognostic factors (pT stage, positive 
surgical margins). Early referral for SART offers better 
disease control after radical prostatectomy. This prospective 
multicenter study confirms outcomes of other series. 
 
 
 
Poster: Clinical track: Urology-non-prostate  
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Purpose or Objective: A bladder-preserving strategy, 
combining transurethral resection of the bladder tumor (TUR-
B) with radiochemotherapy, results in a long-term overall 
survival comparable to cystectomy. However, such a strategy 
is mostly applied to elderly or unfit patients, but their 
medical status regularly contraindicates chemotherapy. This 
leaves the combination of TUR-B and radical radiotherapy as 
the only treatment option. For this vulnerable patient group, 
reduction of toxicity is of additional importance, which could 
be obtained by more conformal treatment plans. It was our 
aim to retrospectively analyze the treatment outcome and 
associated toxicity of both conformal and intensity-
modulated radiotherapy (IMRT) using a tumor boost, for 
locally advanced bladder cancer in patients not suitable for 
cystectomy. 
 
Material and Methods: 119 patients with T1-4 N0-1 M0 
bladder cancer were analyzed retrospectively. Median age 
was 80 years. Patient and treatment characteristics can be 
found in Table 1. Treatment consisted of either a conformal 
box technique or IMRT. Patients were treated with 40 Gy in 
20 fractions to the elective treatment volumes, and a daily 
boost of 0.75 Gy to the tumor. This resulted in a tumor boost 
of either 55 Gy or 60 Gy, the latter in case expected toxicity 
allowed delivery of two additional 2.5 Gy fractions to the 
tumor. Cystoscopic placement of fiducial markers aided in 
tumor delineation. To evaluate response, a cystoscopy was 
performed two months after treatment and thereafter every 
six months. To assess toxicity, patients were seen by their 
oncologist every week during the treatment course, and 
thereafter with 1-12 month intervals until up to 5 years after 
treatment. Toxicity was scored according to the CTCAE 
version 4, with acute toxicity defined as occurring during 
treatment or within the first three months thereafter. The 
Kaplan-Meier method was used to estimate survival and 
locoregional control. Possible predictors for survival were 
examined in univariate Cox proportional hazard regression 
analyses. Differences in toxicity between IMRT or conformal 
radiotherapy were tested using χ2 tests.  
 
 
Results: At 3 months, a complete response was seen in 87% 
of patients. 3-year overall survival was 44%, with a 
locoregional control rate of 72% at three years (Figure 1). 
Including pelvic lymph nodes in the elective field increased 
survival significantly (hazard ratio: 0.58, p = 0.04). Late 
toxicity was low, with urinary and intestinal toxicity grades ≥ 
2 of 14% and 5%, respectively. IMRT reduced late intestinal 
toxicity grade ≥ 1 from 24% to 7% (p=0.04), as well as acute 
intestinal toxicity grade ≥ 2 (from 36% to 12%, p = 0.03). 
